Bolt Biotherapeutics (NASDAQ:BOLT) Posts Quarterly Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) announced its quarterly earnings results on Thursday. The company reported ($3.84) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $2.50 million for the quarter.

Bolt Biotherapeutics Stock Down 1.9%

BOLT stock traded down $0.08 during midday trading on Thursday, reaching $4.05. The company had a trading volume of 6,656 shares, compared to its average volume of 26,692. The company has a current ratio of 3.57, a quick ratio of 3.57 and a debt-to-equity ratio of 0.65. Bolt Biotherapeutics has a 1 year low of $4.01 and a 1 year high of $9.66. The company has a 50 day moving average of $5.46 and a two-hundred day moving average of $5.37. The company has a market capitalization of $7.78 million, a P/E ratio of -0.18 and a beta of 0.94.

Institutional Trading of Bolt Biotherapeutics

Large investors have recently made changes to their positions in the stock. Squarepoint Ops LLC increased its position in Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares during the period. Shay Capital LLC acquired a new stake in shares of Bolt Biotherapeutics in the 3rd quarter valued at $85,000. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics during the third quarter worth about $89,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $112,000. Finally, T3 Companies LLC acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at $208,000. Institutional investors own 86.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, January 21st. Zacks Research downgraded shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $34.00.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.